Citius Oncology, Inc. 宣布了其针对高危弥漫性大B细胞淋巴瘤患者的研究初步顶线数据。该1期临床试验旨在评估Lymphir™(研发代码E7777)在商用嵌合抗原受体T细胞疗法之前给药的安全性与初步疗效。
Citius Oncology, Inc. 宣布了其针对高危弥漫性大B细胞淋巴瘤患者的研究初步顶线数据。该1期临床试验旨在评估Lymphir™(研发代码E7777)在商用嵌合抗原受体T细胞疗法之前给药的安全性与初步疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.